A Note from the Editor

Compass Pathways’ Phase 3 readout dominated this week’s new cycle, as the company shared topline data from the psilocybin for treatment-resistant depression program on Tuesday morning.

It certainly kept us busy! Early on Tuesday morning, we published our analysis of the news, which included discussion with Compass CEO Kabir Nath and CMO Guy Goodwin. Later in the day, we shared our notes from the company’s webcast, during which further data was shared. And, on Friday, we published views from across the field, synthesising what we had heard from researchers, practitioners, and executives.

Elsewhere, two psychedelics trials were published in academic journals this week, providing a more detailed look at methods and outcomes. On Monday, a Phase 2a trial of intravenous DMT for major depressive disorder, carried out by Small Pharma (which has since been acquired by Helus), published in Nature Medicine. Then, on Wednesday, Transcend Therapeutics’ Phase 2 trial of methylone for PTSD published in JAMA Psychiatry.

On Thursday, we shared the latest edition of our Psychedelic Drug Development Pipeline Bullseye Charts, supported by UBC. These visualisations aim to provide a one-stop overview of the pipeline, from discovery through to approval, segmented by molecule and indication.

While our Bullseye Charts show an increase in late-stage trial activity, earlier this week, FDA’s Vinay Prasad and Martin Makary appeared to confirm the agency’s intent to expect just one pivotal trial by default, via a letter in NEJM. We dive deeper in our next Bulletin.

For the next two weeks, Psychedelic Alpha is on the road. I will be speaking at the 6th Annual Psychedelic Therapeutics & Drug Development Conference in New Orleans on Thursday, as well as at an event at the New Orleans BioInnovation Center. I then head to New York and Washington, D.C. If you would like to connect, please do get in touch.

Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelics business, policy, research and beyond.

Josh Hardman
Founder & Editor